Screener
Allogene Therapeutics ALLO Interest Expense
Interest Expense at other companies
Other financials
Where this comes from
Reported directly by Allogene Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:InterestExpenseNonoperating.
The source filing: Allogene Therapeutics’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 4:05 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-034585
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Loss from operations | (46,092) | (65,191) |
| Other income (expenses), net: | ||
| Interest and other income, net | 3,573 | 5,516 |
| Interest expense | (300) | (150) |
| Other income (expenses), net | 212 | 92 |
| Total other income (expenses), net | 3,485 | 5,458 |
| Net loss | (42,607) | (59,733) |
| Other comprehensive income (loss): |
Item 1. Financial Statements - Unaudited
FAQ
- What is Allogene Therapeutics's interest expense?
- Allogene Therapeutics (ALLO) reported interest expense of $300K in Q1 2026.
- How has Allogene Therapeutics's interest expense changed year-over-year?
- Allogene Therapeutics's interest expense increased by 100.0% year-over-year, from $150K to $300K.
- What does interest expense mean?
- Cost of borrowing — interest paid or accrued on bonds, bank loans, credit facilities, finance leases, and other debt obligations.
Ask your AI about Allogene Therapeutics's interest expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude